Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial PharmaphorumRoche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.OncologyRead full story pharminent July 2, 2026 (Last updated: July 2, 2026) Pharmaphorum Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Insilico Medicine, Takeda partner on AI-driven drug discoveryNext: AZ forges ever-closer ties with China’s CSPC Pharma Related Stories Clinical Data GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 fail pharminent July 17, 2026 Clinical Data AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug pharminent July 15, 2026 Clinical Data AAIC 2026: Lilly keeps door open for maintenance Kisunla after amyloid clearance pharminent July 15, 2026
